Abstract
Background: In some epidemiological studies, blood lipids are determined at non-fasting state, which may impact cardiovascular risk estimation. The aim of this study was to evaluate postprandial LDL-C changes in men with newly diagnosed metabolic syndrome (MetSy). Methods: 36 male patients were examined: 12 men with and 24 men without MetSy. The fat tolerance test was performed before and after a three-month hypolipidemic treatment. Serum lipids were measured using routine methods, lipid peroxides (LPO) colorimetrically, apoli- poproteins A-I, B, and hsCRP immunoturbidimetrically. Results: The postprandial increase in triglycerides was associated with a decrease in LDL-C and a small decrease in apo B. In men with MetSy, the mean change in LDL-C (-19.5 ± 2.3 mg/dl) was greater than in healthy men (-5.7 ± 3.8 mg/dl). All lipid changes (ΔTG, ΔLDL-C and ΔLPO) were linearly dependent on the postprandial non-LDL-choles- terol. After three months of hypolipidemic treatment, in all men with MetSy, the apoB/apoA-I ratio remained the same as before the therapy. Conclusion: In men diagnosed with MetSy, postprandial decreases in LDL-cholesterol may cause underestimation of cardiovascular risk. After three months of hypolipidemic treatment, there was only a partial reduction in this risk, as the apoB/apoA-I ratio remained the same.
References
[1] Reaven GM. The Metabolic Syndrome: Requiescat in Pace. Clin Chem. 2005; 51: 931-938 10.1373/clinchem.2005.048611Search in Google Scholar
[2] Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–1645 10.1161/CIRCULATIONAHA.109.192644Search in Google Scholar
[3] Achimastos AD, Efstathiou SP, Christoforatos T, Panagiotou TN, Stergiou GS, Mountokalakis TD. Arterial stiffness: determinants relationship to the metabolic syndrome. Angiology. 2007;58:11-20 10.1177/0003319706295477Search in Google Scholar
[4] Beijers HJ, Henry RM, Bravenboer B, Ferreira I, Dekker JM, Nijpels G, Stehouwer CD.Metabolic Syndrome in Nondiabetic Individuals Associated With Maladaptive Carotid Remodeling: The Hoorn Study.Am J Hypertens. 2011 Jan 6. 10.1038/ajh.2010.256Search in Google Scholar
[Epub ahead of print]. Search in Google Scholar
[5] Tzou WS, Douglas PS, Srinivasan SR, Chen W, Berenson G, Stein JH. Advanced lipoprotein testing does not improve identification of subclinical atherosclerosis in young adults: the Bogalusa Heart Study. ANN Intern Med. 2005;142:742-50 10.7326/0003-4819-142-9-200505030-00009Search in Google Scholar
[6] Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med. 2006;119:812–819 10.1016/j.amjmed.2006.02.031Search in Google Scholar
[7] Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007;49:403–414 10.1016/j.jacc.2006.09.032Search in Google Scholar
[8] Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffrin EL, Eisenberg MJ. The metabolic syndrome and cardiovascular risk. A systematic review and meta-analysis. J Am CollCardiol. 2010;56:1113–1132 10.1016/j.jacc.2010.05.034Search in Google Scholar
[9] Li J, Flammer AJ, Lennon RJ, Nelson RE, Gulati R, Friedman PA, Thomas RJ, Sandhu NP, Hua Q, Lerman LO, Lerman A. Comparison of the effect of the metabolic syndrome and multiple traditional cardiovascular risk factors on vascular function. Mayo Clin Proc. 2012;87:968-75 10.1016/j.mayocp.2012.07.004Search in Google Scholar
[10] Nofer JR, Kehre B, Fobker M, Levkau B, Assman G, von Eckardstein A. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis. 2002;161:1-16. 10.1016/S0021-9150(01)00651-7Search in Google Scholar
[11] Barter P. The role of HDL-cholesterol in preventing atherosclerotic disease. Eur Heart J Suppl 2005;7:F4-F8 10.1093/eurheartj/sui036Search in Google Scholar
[12] Andrews KL, Moore XL, Chin-Dusting JP. Anti-atherogenic effects of high-density lipoprotein on nitric oxide synthesis in the endothelium.Clin Exp Pharmacol Physiol. 2010;37:736-42 10.1111/j.1440-1681.2010.05387.xSearch in Google Scholar
[13] Onat A, Can G, Yüksel H. Dysfunction of high-density lipoprotein and its apolipoproteins: New mechanisms underlying cardiometabolic risk in the population at large Turk Kardiyol Dern Ars. 2012;40:368-85 10.5543/tkda.2012.55490Search in Google Scholar
[14] Calabro P, Yeh ETH. Intra-abdominal adiposity, inflammation, and cardiovascular risk: New insight into global cardiometabolic risk.Current Hypertension Rep. 2008;10:32-38 10.1007/s11906-008-0008-zSearch in Google Scholar
[15] Yuan G, Al-Shali KZ, Hegele R. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ. 2007;176:1113-1120 10.1503/cmaj.060963Search in Google Scholar
[16] Hansel B, Giral P, Nobecourt E, et al. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab. 2004;89:4963-4971 10.1210/jc.2004-0305Search in Google Scholar
[17] Bai H, Liu BW, Deng ZY, Shen T, Fang DZ, Zhao YH, Liu Y. Plasma very-low-density lipoprotein, low-density lipoprotein, and high-density lipoprotein oxidative modification induces procoagulant profiles in endogenous hypertriglyceridemia. Free Radic Biol Med. 2006;40:1796-803 10.1016/j.freeradbiomed.2006.01.007Search in Google Scholar
[18] Kolovou GD, Mikhailidis DP, Kovar J, Lairon D, Nordestgaard BG, Ooi TC, Perez-Martinez P, Bilianou H, Anagnostopoulou K, Panotopoulos G. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol. 2011;9:258-270 10.2174/157016111795495549Search in Google Scholar
[19] Nordestgaard BG, Freiberg JJ. Clinical relevance of non-fasting and postprandial hypertriglyceridemia and remnant cholesterol.CurrVascPharmacol. 2011;9:281-6 Search in Google Scholar
[20] Salazar MR, Carbajal HA, Espeche WG, LeivaSisnieguez CE, Balbín E, Dulbecco CA, Aizpurúa M, Marillet AG, Reaven GM. Relation among the plasma triglyceride/high-density lipoprotein cholesterol concentration ratio, insulin resistance, and associated cardio-metabolic risk factors in men and women. Am J Cardiol. 2012;109:1749-53 10.1016/j.amjcard.2012.02.016Search in Google Scholar
[21] Grundy SM; National Cholesterol Education Program (NCEP)-The National Cholesterol Guidelines in 2001, Adult Treatment Panel (ATP) III. Approach to lipoprotein management in 2001 National Cholesterol Guidelines. Am J Cardiol. 2002; 90:11i-21i 10.1016/S0002-9149(02)02631-0Search in Google Scholar
[22] Fruchart JC, Duriez P. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today. 2006;42:39-64. Search in Google Scholar
[23] Stone NJ, Saxon D. Approach to treatment of the patient with metabolic syndrome: lifestyle therapy.Am J Cardiol. 2005;96:15E-21E 10.1016/j.amjcard.2005.05.010Search in Google Scholar
[24] Goodson BL, Wung SF, Archbold KH. Obstructive sleep apnea hypopnea syndrome and metabolic syndrome: A synergistic cardiovascular risk factor. J Am Acad Nurse Pract. 2012;24:695-703 10.1111/j.1745-7599.2012.00771.xSearch in Google Scholar
[25] Walldius G, Aastveit AH, Jungner I. Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study. J Intern Med. 2006;259:259-66 10.1111/j.1365-2796.2005.01610.xSearch in Google Scholar
[26] Jungner I, Sniderman AD, Furberg C, Aastveit AH, Holme I, Walldius G. Does low-density lipoprotein size add to atherogenic particle number in predicting the risk of fatal myocardial infarction? Am J Cardiol. 2006;97:943-6 10.1016/j.amjcard.2005.10.062Search in Google Scholar
[27] Contois JH, Warnick GR, Sniderman AD. Reliability of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B measurement. J Clin Lipidol. 2011;5:264-72 10.1016/j.jacl.2011.05.004Search in Google Scholar
[28] Walldius G. Apolipoprotein B (apoB) more closely related to subclinical atherosclerosis than non-HDL cholesterol and LDL cholesterol. J Intern Med. 2010;268:549-51 10.1111/j.1365-2796.2010.02286.xSearch in Google Scholar
[29] Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J, Furberg CD. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk.CircCardiovascQual Outcomes. 2011;4:337-452 10.1161/CIRCOUTCOMES.110.959247Search in Google Scholar
[30] Sundvall J, Leiviskä J, Laatikainen T, Peltonen M, Salomaa V, Vanhala M, Korpi-Hyövälti E, Lauronen J, Alfthan G. The use of fasting vs. non-fasting triglyceride concentration for estimating the prevalence of high LDL-cholesterol and metabolicsyndrome in population surveys. BMC Med Res Methodol. 2011;11:63 10.1186/1471-2288-11-63Search in Google Scholar
[31] Lund SS, Petersen M, Frandsen M, Smidt UM, Parving HH, Vaag AA, Jensen T.Agreement between fasting and postprandialLDLcholesterolmeasured with 3methods in patients with type2diabetesmellitus. Clin Chem. 2011;57:298-308 10.1373/clinchem.2009.133868Search in Google Scholar
[32] Liskum L. Cholesterol biosynthesis. New Comprehensive Biochemistry. 2002;36: 409-432 10.1016/S0167-7306(02)36017-4Search in Google Scholar
[33] Ruge T, Sukonina V, Kroupa O, Makoveichuk E, Lundgren M, Svensson MK, Olivecrona G, Eriksson JW. Effects of hyperinsulinemia on lipoprotein lipase, angiopoietin-like protein 4, and glycosylphosphatidylinositol-anchored high-density lipoprotein binding protein 1 in subjects with and without type 2 diabetes mellitus. Metabolism. 2012;61:652-60 10.1016/j.metabol.2011.09.014Search in Google Scholar PubMed
[34] Zélie J, Fournier N, Bellanger N, Chapman MJ, Goff WL, Guerin M. Postprandial lipemiaenhances the capacity of large HDL2 particles to mediate free cholesterol efflux via SR-BI and ABCG1 pathways in type IIB hyperlipidemia. J Lipid Res. 2010;51:3350-3358 10.1194/jlr.P009746Search in Google Scholar PubMed PubMed Central
[35] Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, Taskinen MR. Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome. Diabetes Care. 2001; 24:683–689. 10.2337/diacare.24.4.683Search in Google Scholar PubMed
[36] Virani SS, Wang D, Woodard LD, Chitwod SS, Landrum CR, Zieve FJ, Ballantyne CM, Petersen LA. Non–high-density lipoprotein cholesterol reporting and goal attainment in primary care. J Clin Lipidol. 2012;6:545-552 10.1016/j.jacl.2012.04.080Search in Google Scholar PubMed
[37] Stancliffe RA, Thorpe T, Zemel MB. Dairy attentuates oxidative and inflammatory stress in metabolic syndrome. Am J ClinNutr. 2011;94:422-430 10.3945/ajcn.111.013342Search in Google Scholar PubMed PubMed Central
[38] Pravenec M, Kajiya T, Zídek V, Landa V, Mlejnek P, Simáková M, Silhavý J, Malínská H, Oliyarnyk O, Kazdová L, Fan J, Wang J, Kurtz TW. Effects of human C-reactive protein on pathogenesis of features of the metabolic syndrome. Hypertension. 2011;57:731-737 10.1161/HYPERTENSIONAHA.110.164350Search in Google Scholar PubMed PubMed Central
[39] Mazloom Z, Hejazi N, Dabbaghmanesh MH, Tabatabaei HR, Ahmadi A, Ansar H. Effect of vitamin C supplementation on postprandial oxidative stress and lipid profile in type 2 diabeticpatients. Pak J Biol Sci. 2011;14:900-904 10.3923/pjbs.2011.900.904Search in Google Scholar PubMed
[40] Spiteller G.The relation of lipid peroxidation processes with atherogenesis: a new theory on atherogenesis. Mol Nutr Food Res. 2005;49:999-1013 10.1002/mnfr.200500055Search in Google Scholar PubMed
© 2015 A. Skoczyńska et al.
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
